Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2026-02-06 Director's Dealing
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2026-02-06 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes references to Regulation FD Disclosure, exhibits such as a corporate presentation, an interim clinical progress update, and a press release. It explicitly states that the information is "furnished" and not "filed," indicating it is an event disclosure rather than a full financial report. There are no detailed financial statements or comprehensive financial data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, audit report, or governance information. It is a regulatory filing announcing current events and disclosures. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7335 characters) and content support this classification with high confidence.
2026-02-05 English
S-1/A Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement Amendment No. 2 filed with the SEC by AIM ImmunoTech Inc. It is a registration statement under the Securities Act of 1933 for a Rights Offering involving subscription rights to purchase units consisting of preferred stock and warrants. The document is a preliminary prospectus describing the terms of the offering, subscription rights, pricing, and related details. It is not a financial report, earnings release, or management discussion. It is a capital raising filing related to financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a certification, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2026-01-29 English
S-1/A Filing
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement Amendment No. 1 filed with the SEC by AIM ImmunoTech Inc. It is a detailed prospectus related to a Rights Offering involving subscription rights to purchase units consisting of preferred stock and warrants. The document includes detailed information about the offering, subscription rights, terms, risk factors, use of proceeds, and other related disclosures. This type of filing is a registration statement for securities offerings under the Securities Act of 1933, which is a capital raising activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or a brief summary, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the correct classification is CAP with high confidence.
2026-01-23 English
AIM Notice - 21/01/2026
Share Issue/Capital Change Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange detailing the admission of new ordinary shares to trading on the AIM market for multiple companies. This constitutes an announcement of new share issues and capital changes. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the most accurate category for announcements regarding new share issues.
2026-01-21 English
AIM Notice - 20/01/2026
Regulatory Filings Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange detailing the admission of new securities to trading on the AIM market. It lists specific companies and the number of ordinary shares being admitted. This falls under the category of share issuance or capital changes, specifically fitting the 'Share Issue/Capital Change' (SHA) category as it reports the official admission of new shares to the exchange.
2026-01-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.